AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity - Wikidata - wikimedia - TriplyDB

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

http://www.wikidata.org/entity/Q34511038

about

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer Resistant mechanisms to BRAF inhibitors in melanoma Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells MEK and PI3K inhibition in solid tumors: rationale and evidence to date PI3K and AKT: Unfaithful Partners in Cancer Targeting Breast Cancer Metastasis Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion Adaptive resistance to targeted therapies in cancer Ten things you should know about protein kinases: IUPHAR Review 14 Targeting the mTOR signaling pathway in neuroendocrine tumors The dynamic nature of the kinome Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer Beyond BRAF: where next for melanoma therapy?An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy Maximising the potential of AKT inhibitors as anti-cancer treatments The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?The phosphoinositide 3-kinase pathway and therapy resistance in cancer Mapping the Pathways of Resistance to Targeted Therapies PTEN is a protein tyrosine phosphatase for IRS1 Mechanisms of action of therapeutic antibodies for cancer Systematic identification of combinatorial drivers and targets in cancer cell lines Perturbation biology: inferring signaling networks in cellular systems Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas Cellular effects of HER3-specific affibody molecules PI3K and cancer: lessons, challenges and opportunities Network Architecture Predisposes an Enzyme to Either Pharmacologic or Genetic Targeting.p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.

P2860

Q24338724-1C28F5B7-3831-4639-ACE0-F01395B0D89F Q26739717-2A455D9A-5795-4803-B0CC-AD653893E1EE Q26774625-71DDBBE0-9F3A-4E09-BF97-AFAD3A5CC293 Q26775573-4B7E4053-C9F3-45FD-850F-BBD5539032F3 Q26781367-FA64660A-4FEB-4AD8-964A-B0D042DF82FC Q26783925-D84484C7-55E3-479C-9D89-91033CAAAA85 Q26796364-C7AFBE87-1AB8-411B-A320-89C670A10833 Q26849316-C4141E77-7DB7-481D-A751-22E7636E0448 Q26849417-AFFBDE19-942C-468C-9792-49F5E7D7D81F Q26852089-46D87C87-7E62-4EBD-B9F7-BC86BBC5641F Q26852588-86F22039-16E0-4C37-85D1-BA5B63CA25BC Q26862550-3FB41E62-3393-4A6F-AB9F-2FF5375C7D63 Q27006853-33B705A9-92D0-4CD1-A2EF-7D74011A6193 Q27679463-9F40F665-6522-4EAD-89C1-8E1D02C4EFC2 Q27711042-4A383351-3130-4DD5-8477-4C23A3975BE4 Q27851975-8E7D42F7-F011-4CDC-9792-5C93101EB4B8 Q27852473-C709E48A-6288-4012-A985-85AFFEFF5A22 Q27852528-6D12CDE2-5127-4858-A045-63BD95A3E468 Q27852637-E02C0921-1EA5-4C1A-BD26-27A52AE41FA5 Q28070028-AAD529E1-A825-4551-8F37-3AB0BA5F12DE Q28072254-0DB25110-8A13-4774-960A-1C236F4370D1 Q28074203-BD2F6B54-440C-451A-B505-28550E380DEA Q28076402-E7FB929E-A182-4253-BB64-46C323E063CB Q28079596-93B9DFE7-BB0E-44E2-820B-49519676A92E Q28082811-F9E8D3A3-8B48-46AE-A772-A1571FFD4BC1 Q28088791-D8E99791-5876-473F-AB0B-04775043C9FF Q28239790-6548437B-C450-46C5-891B-080B0DA6150C Q28385366-DAD03E0F-B75B-46A4-9847-27DFA89461A4 Q28486051-F1B5858A-A4B2-4339-9AEC-B839E536F9BF Q28537769-190D7E5B-3B50-4F0D-967D-5B36C05884AB Q28540161-831AF522-CDE0-4D8C-8362-D7060298D8EB Q28540918-1389FB89-6D6B-4952-98EF-536D81DA1DE8 Q28547399-8A019D58-B5C3-4B44-985D-28A8F7FEE5F2 Q28548486-3DCB8370-47B0-4945-B25C-514C0C75E081 Q28551145-8EB8697B-8D45-4E83-94EF-4CA6CAF5F5D5 Q28602310-13BF38D6-D476-4CAB-8FB0-B7FDBCD948E0 Q28727774-FC0F787A-6A0A-404B-9070-3C7956E2EAA7 Q30080017-4E5D81ED-1AFD-4F95-858B-186B45DA0D1C Q30277214-8941B02C-4E75-4A1C-9979-DA03360953F9 Q30371561-4AB36DD6-2BA9-4753-8509-DD084454B16E

P2860

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

http://www.wikidata.org/entity/Q34511038

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

AKT inhibition relieves feedba ...... kinase expression and activity

@ast

AKT inhibition relieves feedba ...... kinase expression and activity

@en

AKT inhibition relieves feedba ...... kinase expression and activity

@nl

type

label

AKT inhibition relieves feedba ...... kinase expression and activity

@ast

AKT inhibition relieves feedba ...... kinase expression and activity

@en

AKT inhibition relieves feedba ...... kinase expression and activity

@nl

prefLabel

AKT inhibition relieves feedba ...... kinase expression and activity

@ast

AKT inhibition relieves feedba ...... kinase expression and activity

@en

AKT inhibition relieves feedba ...... kinase expression and activity

@nl

P1433

Q34511038-7FA54AE0-495A-411B-8C5C-0A7FC24AA97E

P1476

Q34511038-5A9AAA2D-6643-4801-AB88-51B227A22B28

P2093

Q34511038-0088561C-E2F1-405D-907D-31978A098A9D

Q34511038-1219FA21-07B6-48A8-BBF7-05E24314174C

Q34511038-30B5DBE6-D575-4C50-97AD-B56C0B5CA3A2

Q34511038-4BCDEBA8-7D0E-4E7F-8450-9848EC2A07EB

Q34511038-A064A598-A06B-4A99-876D-3D1750AC5CCA

Q34511038-C8F9FD9C-33C8-409E-AD54-E9C5E9B1DF61

Q34511038-CEBB6B64-BBC3-44F5-B065-14B88946BF19

P2860

Q34511038-0CD88B6A-0F5E-489A-8995-181D8DC3E239

Q34511038-0F1AB28B-6DE4-4955-B2B0-D3FCE0B7F95C

Q34511038-10A0F3A3-421E-47F2-8475-5B6445EF1D51

Q34511038-17694A2F-1D91-4D09-93D6-8285B91247AD

Q34511038-208FCFCD-CFF7-42DF-AD1F-2DD074953C2A

Q34511038-25B17B58-982D-495C-98CB-88443FDD0276

Q34511038-2C129893-666D-4317-AB1A-CFD5DBCD7BB5

Q34511038-2E22B55D-47CC-4DDE-9A09-E0067ED6AA1E

Q34511038-39D5045F-90B2-4FCF-B266-EACE47BC742B

Q34511038-52B4B561-DC30-4CA1-9AC8-4140FC71949F

P304

Q34511038-5D289926-E8DF-4FBD-862F-BFB921D52D21

P31

Q34511038-76EB50C9-7234-40E7-A799-0E904A2FF58B

P356

Q34511038-D5BE59B0-94FB-4880-A8F5-08825735D843

P433

Q34511038-C3133C1E-45CE-4EBE-8B5B-4267FCC48D81

P478

Q34511038-D3C7AA11-5953-4EC5-8234-62208511E8D0

P50

Q34511038-A63F071D-F70E-4EC5-AE39-AFB83B2E30DA

Q34511038-BE9BF143-CC6D-41DF-9DAA-359AA816151A

P577

Q34511038-C753F40A-C519-4F8C-B442-75549F3F0105

P5875

Q34511038-DB214371-8B81-47AA-B844-4725C1B23E4A

P698

Q34511038-9B5EB6CA-0DF4-419C-87B4-1ACFE8EC815A

P932

Q34511038-6501A7CA-8CA5-4C74-B153-9846A3A7AA34

P356

J.CCR.2010.10.031

P1433

P1476

AKT inhibition relieves feedba ...... kinase expression and activity

@en

P2093

Ayana Sawai

http://www.w3.org/2001/XMLSchema#string

Maurizio Scaltriti

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

Olivera Grbovic-Huezo

http://www.w3.org/2001/XMLSchema#string

Pradip K Majumder

http://www.w3.org/2001/XMLSchema#string

Sarat Chandarlapaty

http://www.w3.org/2001/XMLSchema#string

Vanessa Rodrik-Outmezguine

http://www.w3.org/2001/XMLSchema#string

P2860

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

Direct control of the Forkhead transcription factor AFX by protein kinase B

The PI3K pathway as drug target in human cancer

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

A C. elegans mutant that lives twice as long as wild type

Defining the role of mTOR in cancer

The emerging roles of forkhead box (Fox) proteins in cancer

P304

58-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2010.10.031

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49737779

http://www.w3.org/2001/XMLSchema#string

P698

21215704

http://www.w3.org/2001/XMLSchema#string

P932

3025058

http://www.w3.org/2001/XMLSchema#string